Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics has secured an additional £5 million from its amended loan facility with major shareholders, extending its financial runway into late September. The company still has access to £12.5 million of uncommitted funds and is exploring further financing options to support operations and its development pipeline.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
